Registry study for genetic profiling of adult-type diffuse gliomas in Taiwan

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to establish a comprehensive registry for adult-type diffuse gliomas in Taiwan, focusing on their genetic and molecular profiles through next-generation sequencing. The study will analyze the impact of these profiles on treatment outcomes and disease progression. By collecting and storing clinical data alongside tumor samples, the research seeks to enhance personalized therapy and develop novel treatment strategies for patients suffering from these aggressive brain tumors.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Pathological confirmation or suggestion of adult-type diffuse gliomas A. Diagnosis includes glioblastoma, astrocytoma, oligodendrocytoma that is listed in ATDG category per WHO criteria.

   B. Gliomas that are preferred as ATDGs from pathological and clinical views, but not given for confirmed diagnosis.
2. Willingness to provide archival or newly obtained tumor tissues for current study proposal.
3. Age equal or more than 20 years old (inform consent).
4. Life expectancy more than 3 months.
5. Patients fully understand the protocol with the willingness to have regular follow-up.
6. Additional criteria for individual arms A. \[Arm 1\] Within 2 months after surgery for primary tumor. B. \[Arm 2\] Total resection of primary tumors with tissue samples available for test.

C. \[Arm 3\] (1) Total resection of primary tumors with the paired primary and recurrent tissue samples available for test. (2) IDH test suggesting wild-type.

Exclusion Criteria:

1. Gliomas diagnosed or preferred as other categories than ATDGs, such as pediatric-type diffuse gliomas, circumscribed astrocytic gliomas, and others.
2. Inability to cooperate by providing a complete medical history.
3. Patients disagree to provide archived tumor samples.
4. Undesirable compliance.
5. Having a known additional malignancy that is progressing or has required active treatment within the past 3 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., cervical carcinoma in situ) that have undergone potentially curative therapy are not excluded.

Where it's running

• Kaohsiung Chang Gung Memorial Hospital
  Kaohsiung City, Taiwan Recruiting
• Shuang Ho Hospital
  New Taipei City, Taiwan Recruiting
• China Medical University Hospital
  Taichung, Taiwan Recruiting
• Taichung Veterans General Hospital
  Taichung, Taiwan Recruiting
• National Cheng Kung University Hospital
  Tainan, Taiwan Recruiting
• National Taiwan University Hospital
  Taipei, Taiwan Recruiting

Study contacts

• Principal investigator: Yong-Kwang Tu, MD, PhD — Taipei Neuroscience Institute,Taipei Medical University
• Study coordinator: Chien-Ya Hung
• Email: 951106@nhri.edu.tw
• Phone: +886-3-7206166

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HSK42360 treatment for children with malignant brain tumors that have a BRAF V600 mutation

  This trial tests whether the oral drug HSK42360 is safe and tolerable in children aged 6 to under 18 who have recurrent malignant brain tumors with a BRAF V600 mutation.

  Recruiting at 6 sites Phase 1 Haisco Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 5 other locations · NCT07158710

• Boron neutron capture treatment with B10 L-BPA for malignant brain tumors

  This trial will test boron neutron capture therapy using B10 L-BPA in adults with WHO grade 3 or 4 malignant brain tumors to see if it is safe and can shrink tumors.

  Recruiting at 2 sites Phase 1/2 China Medical University Hospital · Hsinchu and 1 other locations · NCT07003139

• Combined intracranial and intravenous NK cell therapy for malignant brain tumors

  This trial will test whether giving adults with recurrent malignant brain tumors their own expanded and activated natural killer (NK) cells into the tumor site and into the bloodstream is safe and feasible.

  Recruiting at 3 sites Peking University Third Hospital · Beijing, Beijing Municipality and 3 other locations · NCT07552233

• Pharmacoscopy-guided treatment for refractory brain tumors

  This trial tests whether personalized drug testing on a patient’s tumor cells can guide treatment choices for adults with hard-to-treat brain cancers like glioblastoma.

  Recruiting Phase 2 University of Zurich · Basel, Basel-Landschaft and 2 other locations · NCT06804655

• Proton versus photon radiation for adults with primary brain tumors

  This trial will test whether proton beam radiation causes fewer long-term side effects than standard photon (X-ray) radiation in adults aged 18–70 with primary brain tumors who are expected to live more than five years.

  Recruiting Tata Memorial Centre · Mumbai · NCT06831461

• Combining mirdametinib and vorinostat for treating specific nerve tumors in NF1 patients

  This study is testing a new combination of two medications to see if they can help patients with a specific type of nerve tumor related to Neurofibromatosis type 1 before starting regular treatments.

  Recruiting Early Phase 1 University of Minnesota · Minneapolis, Minnesota · NCT06693284

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.